FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.98
-0.02 (-0.13%)
As of 12:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close16.00
Open15.93
Bid15.96 x 900
Ask15.98 x 200
Day's Range15.78 - 16.01
52 Week Range11.44 - 17.62
Volume230,066
Avg. Volume2,235,604
Market Cap3.012B
Beta1.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE24 days ago

    Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...

  • GlobeNewswire27 days ago

    Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced today regulatory and clinical advancements in its development program for AT-GAA for Pompe disease following guidance from regulators in the European Union as well as guidance on manufacturing and bio-comparability from German regulatory authorities (BfArM). 2) to discuss whether Amicus may pursue a pathway for AT-GAA that includes a conditional marketing approval (CMA) application in Europe.  Amicus has concluded this series of interactions and has now received written guidance from the SAWP.

  • GlobeNewswirelast month

    Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of  the Company’s President and Chief Operating Officer Bradley L. Campbell to its Board of Directors, effective immediately. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “On behalf of our Board of Directors, I am pleased to announce Bradley’s appointment to the Board.

  • GlobeNewswire2 months ago

    Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

    CRANBURY, N.J., June 01, 2018-- Amicus Therapeutics, Inc. announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming ...

  • GlobeNewswire2 months ago

    Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan

    Amicus Therapeutics (FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold® capsules 123mg (migalastat) for treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Galafold is the first and only oral precision medicine for Fabry disease in Japan. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “The launch of Galafold in Japan, less than one year after our J-NDA submission, provides a significant opportunity for us to deliver this oral and differentiated precision medicine to amenable Fabry patients living in Japan.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / U.S. markets were weighed down by the energy sector on Thursday as U.S. crude oil prices closed lower for the third consecutive session. However, major indexes ...

  • ACCESSWIRE2 months ago

    Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks

    Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics

    NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to close at 2,711.45.

  • GlobeNewswire2 months ago

    Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference

    CRANBURY, N.J., May 09, 2018-- Amicus Therapeutics today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 ...

  • GlobeNewswire2 months ago

    Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates

    Continued Global Galafold ® Adoption and Expansion– Reaffirms FY18 Revenue Guidance of $75 M- $85 M at Top End of Range. Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities- ...

  • GlobeNewswire3 months ago

    Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018

    CRANBURY, N.J., April 26, 2018-- Amicus Therapeutics today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics

    NEW YORK, NY / ACCESSWIRE / March 1, 2018 / U.S. markets closed lower Wednesday to end February in the red, with the Dow Jones and S&P 500 breaking its longest monthly gain streak since 1959. The Dow Jones ...

  • ACCESSWIRE5 months ago

    Amicus Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 AM ...